REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:REGN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/13	14:00	GlobeNewswire Inc.	Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/08	19:00	GlobeNewswire Inc.	Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/07	05:20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/07	05:05	GlobeNewswire Inc.	Regeneron Announces Investor Conference Presentations	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/05/02	19:30	GlobeNewswire Inc.	Regeneron Reports First Quarter 2024 Financial and Operating Results	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/29	20:00	GlobeNewswire Inc.	EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/25	20:00	GlobeNewswire Inc.	Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/24	23:05	GlobeNewswire Inc.	Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/23	06:54	GlobeNewswire Inc.	Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/16	20:18	IH Market News	Ericsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More News	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/11	20:24	IH Market News	Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/08	05:00	GlobeNewswire Inc.	Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/04/02	05:05	GlobeNewswire Inc.	Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/25	20:00	GlobeNewswire Inc.	Regeneron Provides Update on Biologics License Application for Odronextamab	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/13	12:55	PR Newswire (US)	High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/13	10:30	GlobeNewswire Inc.	High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/11	20:00	GlobeNewswire Inc.	Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/08	21:00	GlobeNewswire Inc.	EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/06	06:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/06	06:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/03/02	06:14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/29	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/29	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/29	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/27	06:34	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/27	06:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/27	06:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/27	06:07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/27	06:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc
2024/02/27	05:25	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:REGN	Regeneron Pharmaceuticals Inc